Thomas Woiwode is Director at CRISPR Therapeutics AG (CRSP). They have made 15 open-market trades across 6 companies since 2016, most recently 2022-04-29.
CIK 0001619294
6 open-market purchases totalling $29.8M since 2016, against 9 sales. Across 6 scored buys the stock is up 33.2% at ninety days, and 29.6 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 67% | 50% | 67% |
| Avg Move | -2.0% | +37.1% | +33.2% |
| Alpha | +0.8% | +38.6% | +29.6% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TPST | BUY | 2022-04-29 | 2022-05-03 | $2.36 | $10.0M | -28.5% | -25.1% | -47.9% |
| GRTS | BUY | 2020-12-30 | 2021-01-04 | $3.71 | $10.0M | +22.8% | +237.7% | +108.5% |
| ALGS | BUY | 2020-10-20 | 2020-10-20 | $15.00 | $3.0M | +11.3% | +48.3% | +132.0% |
| PASG | BUY | 2020-03-03 | 2020-03-03 | $18.00 | $4.0M | -23.6% | -25.3% | +7.9% |
| CRSP | SELL | 2018-05-15 | 2018-05-17 | $57.99 | $2.6M | +13.2% | -3.7% | -27.6% |
| CRSP | SELL | 2018-05-08 | 2018-05-09 | $51.45 | $85K | +26.0% | +33.0% | -5.1% |
| CRSP | SELL | 2018-05-07 | 2018-05-09 | $50.39 | $6.1M | +26.0% | +33.0% | -5.1% |
| CRSP | SELL | 2018-05-07 | 2018-05-09 | $50.37 | $6.0M | +26.0% | +33.0% | -5.1% |
| CRSP | SELL | 2018-04-30 | 2018-05-02 | $50.29 | $3.0M | +17.3% | +38.7% | -1.3% |
| CRSP | SELL | 2018-04-26 | 2018-04-30 | $50.11 | $22.2M | +11.0% | +56.7% | +0.4% |
| CRSP | SELL | 2018-04-24 | 2018-04-26 | $50.99 | $1.2M | +3.9% | +37.8% | +1.6% |
| CRSP | SELL | 2018-04-23 | 2018-04-24 | $50.67 | $10.1M | +3.6% | +47.0% | +20.9% |
| CRSP | SELL | 2017-12-22 | 2017-12-27 | $20.29 | $124K | +19.9% | +85.6% | +110.1% |
| CRSP | SELL · 10b5-1 | 2017-11-24 | 2017-11-28 | $20.21 | $38K | -2.8% | +9.4% | +148.9% |
| CRSP | BUY | 2016-10-24 | 2016-12-23 | $14.00 | $2.3M | +4.4% | -14.1% | -17.5% |
| BOLD | BUY | 2016-07-25 | 2016-07-25 | $15.00 | $525K | +1.4% | +1.3% | +16.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| Total |
| $38.1M |
Shares reported on the most recent Form 4, priced at the 2022-05-03 close.